Navigation Links
LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
Date:4/20/2009

COPENHAGEN, April 20 /PRNewswire/ -- Santaris Pharma announced today promising findings on the in vitro and in vivo activity of microRNA-targeted therapeutics against cancer developed on the basis of its proprietary Locked Nucleic Acid (LNA) Drug Platform. In both in vitro and in vivo models Santaris Pharma's cancer targeted LNA-antimiR(R)'s demonstrated outstanding recognition and inhibition of disease-associated microRNAs due to their high specificity and affinity. The findings were presented this week at the AACR Meeting in Colorado at a symposium on microRNAs and human cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Santaris Pharma has made significant progress in advancing a rich pipeline of clinical and preclinical drug candidates targeting disease related RNAs, including microRNAs," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer. "These results are another demonstration of the fact that our small, single-stranded oligonucleotides have great potential in relation to the development of microRNA targeting therapeutics within a range of disease areas."

Santaris Pharma is a leader within microRNA research and is collaborating with scientists world-wide to exploit the advantages of the LNA chemistry to design and develop effective and safe antimiRs against a broad range of diseases, including cancer.

Santaris Pharma (founded in 2003) is a privately held clinical stage biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and up-front payments.

    For further information please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com
   http://www.santaris.com


'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
2. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. TauTaTis Discovers Potent Inhibitor of Parkinsons Disease Gene Activity
5. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
6. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
7. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
8. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
9. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
10. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
11. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):